1919

• After the end of the war, the veterinarian Otto Waldmann was entrusted with the task of continung Friedrich Löffler’s research work on the Island of Riems. Activities were still focused on foot-and-mouth disease (FMD) and on the production of an FMD- hyperimmune serum.

1920

• Conversion of the Riems facility into a modern research institute of the “Landwirtschaftsministerium” (Ministry of Agriculture).

1938

• Waldmann and Köbe produced an FMD-vaccine which came to use during the FMD epidemic of the years 1937 – 1938.

1945

• Part of the equipment and furniture was removed as reparations and was lost.

1948

• Heinz Röhrer was appointed head of the "Forschungsanstalt für Tierseuchen Insel Riems" (Research Institute for Animal Diseases, Island of Riems) which was then subordinated to the Academy of Agricultural Sciences of the fthen GDR.
• In addition to research on foot-and-mouth disease, the research programme of the institute was extended to other viral diseases of farm animals.

1951

• Foot-and-mouth disease vaccine concentrate established the basis for the immunization of all cattle older than two years against foot-and-mouth disease.
• Numerous European countries followed this example.

1952

• At the occasion of Friedrich Loeffler's 100th birthday in 1952 and after years of reconstruction and modernisation the institute was named after its founder Friedrich-Loeffler-Institut. „Friedrich-Loeffler-Institut“

1970 - 1985

• Intensive applied research activities advanced the production of vaccines considerably.
• Numerous new vaccines and diagnostics were introduced onto the market. They include for instance such still well known preparations as RIEMSER® Schweinepestvakzine, RIEMSER® IBR/IPV-Vakzine, RIEMSER® Rinderleukose-Testbesteck.

1990

• The production department of the Friedrich-Löffler Research Institute for Animal Diseases, Island of Riems, was affiliated to RIEMSER Tierarzneimittel GmbH.

1992

• RIEMSER Tierarzneimittel GmbH was privatised by the Braun family. The company realised a turnover of 1.1 million Euro and had 30 employees.

1996

• Commissioning of a new logistic centre with eight warehouses to ensure the further business expansion of the Riems company.

1997

• Acquisition of Floracell Kosmetik, Rheinland-Palatinate.
• Change of name to RIEMSER Arzneimittel GmbH.

1998

• Noteworthy company growth by purchase of market authorisations from international pharmaceutical companies such as Wyeth, Solvy, Johnson & Johnson, Knoll, Akzo, GlaxoSmithKline.
• The company acquired patents and pharmaceutical dossiers and presented its own promising research results.

2002

• Takeover of the Pharma Dessau GmbH together with the research project Hylase.
• Further intensification of hylase- research
• Acquisition of 60 % of the DeGAB Pharma GmbH & Co. KG, in Münster, Westphalia
• Development of sales and distribution for oncological preparations
• Completion of preclinical CHP-studies, begin of clinical trials (I and II).
• 1 July 2002, overtaking of Bioglan Pharma GmbH, Gießen

2003

• Takeover of business divisions (needle free injection systems and measurement engineering) of the insolvent Rösch AG in Berlin

2004

• Takeover of all assets from Dr. Herbrand KG, Gengenbach, Black Forrest

2005

• Takeover of all assets from Sanavita AG & Co., Werne, North-Rhine - Westphalia

2006

• Takeover of Fatol Arzneimittel GmbH, Schiffweiler

2007

• Acquisition of international rights for cardiavascular preparations such as Ismo, Lanitop, Lanicor, Spiroctan, Sali-Spiroctan and Aldactone
• Takeover of the operational business including all staff members of the Bionic Solution Management GmbH, Greifswald

2008

• Participation of the General Electric Equity (GE)
• Takeover of the entire dental business of Curasan in Kleinostheim and its American subsidiary - the Riemser Inc. - Raleigh, North Carolina
• The Riemser AG acquires all shares of the prestigious Rentschler Pharma GmbH in Laupheim near Ulm, and thus a further production site
• Dr. Gordon Guth is the new Chief Finance